Drug intelligence / Profile preview

Digicomag

Development stage: Unknown
Lead developer: Gypto Pharma
Modality: Small Molecules
Administration: Oral

Overview

Digicomag is an approved antacid combination product developed and marketed by Gypto Pharma in Egypt. It contains three active ingredients: calcium carbonate (680 mg), magnesium carbonate (80 mg), and simethicone (25 mg). Calcium and magnesium carbonates function as antacids by neutralizing gastric acid, thereby relieving symptoms of hyperacidity such as heartburn and gastric pain. Simethicone acts as an anti-foaming agent to reduce the surface tension of gas bubbles, facilitating their expulsion and relieving bloating and gastric fullness. It is administered orally as a chewable tablet and is indicated for the relief of gastric hyperacidity, heartburn, upset stomach, and nausea.

Brand names: Digicomag
Other names: Digicomag Chewable Tablets

Beyond the preview

Go deeper on Digicomag.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Digicomag.

Explore the full profile